Jaypirca (pirtobrutinib) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient meets ONE of the following (i or ii):
• i. Patient has resistance or intolerance to Imbruvica (ibrutinib), Calquence (acalabrutinib), or Brukinsa (zanubrutinib)
• OR ii. Patient has relapsed or refractory disease AND has tried a Bruton tyrosine kinase (BTK) inhibitor AND has tried at least one B-cell lymphoma-2 (BCL-2) inhibitor (e.g., Venclexta [venetoclax])

Approval duration

1 year